LOXO-292

E561037

small molecule drug targeted cancer therapy tyrosine kinase inhibitor

LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.

Try in SPARQL Jump to: Statements Referenced by

Statements (48)

Predicate	Object
instanceOf	small molecule drug ⓘ targeted cancer therapy ⓘ tyrosine kinase inhibitor ⓘ
belongsToDrugClass	antineoplastic and immunomodulating agents ⓘ protein kinase inhibitors ⓘ
designedFor	RET-altered cancers ⓘ
hasATCCode	L01EX19 ⓘ
hasBlackBoxWarning	QT interval prolongation ⓘ hemorrhagic events ⓘ hepatotoxicity ⓘ hypersensitivity reactions ⓘ hypertension ⓘ
hasBrandName	Retevmo NERFINISHED ⓘ
hasClinicalTrialIdentifier	LIBRETTO-001 ⓘ LIBRETTO-121 NERFINISHED ⓘ LIBRETTO-321 NERFINISHED ⓘ
hasDeveloper	Eli Lilly and Company NERFINISHED ⓘ Loxo Oncology NERFINISHED ⓘ
hasEffect	inhibition of RET-mediated signaling pathways ⓘ reduction of tumor growth in RET-altered cancers ⓘ
hasInternationalNonproprietaryName	selpercatinib NERFINISHED ⓘ
hasMolecularTarget	RET NERFINISHED ⓘ RET activating mutations ⓘ RET fusions ⓘ
hasRegulatoryAgency	European Medicines Agency NERFINISHED ⓘ U.S. Food and Drug Administration NERFINISHED ⓘ
hasSynonym	Retevmo NERFINISHED ⓘ selpercatinib ⓘ
hasUSFDADesignation	breakthrough therapy ⓘ orphan drug ⓘ priority review ⓘ
indication	RET fusion-positive non-small cell lung cancer ⓘ RET fusion-positive thyroid cancer ⓘ RET-mutant medullary thyroid carcinoma ⓘ advanced or metastatic RET-altered solid tumors ⓘ
isAdministeredAs	oral capsules ⓘ
isIndicatedFor	adult and pediatric patients 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer ⓘ adult and pediatric patients 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer ⓘ adult patients with RET fusion-positive non-small cell lung cancer ⓘ
isMetabolizedBy	CYP3A4 NERFINISHED ⓘ
isSelectiveFor	RET over other kinases ⓘ
mechanismOfAction	selective RET receptor tyrosine kinase inhibition ⓘ
receivedUSFDAApprovalFor	advanced or metastatic RET fusion-positive thyroid cancer ⓘ advanced or metastatic RET-mutant medullary thyroid cancer ⓘ metastatic RET fusion-positive non-small cell lung cancer ⓘ
routeOfAdministration	oral ⓘ
targets	RET kinase NERFINISHED ⓘ
usedInCombinationWith	other anticancer therapies in some treatment regimens ⓘ

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

Loxo Oncology (acquired) → developedDrug → LOXO-292 ⓘ

subject surface form: Loxo Oncology

Loxo Oncology (acquired) → secondMajorProductAlsoKnownAs → LOXO-292 ⓘ

subject surface form: Loxo Oncology